S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Copper Exploration Heating Up (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
NYSE:NGVT

Ingevity - NGVT Stock Forecast, Price & News

$68.91
+0.19 (+0.28%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$68.13
$70.25
50-Day Range
$60.69
$74.10
52-Week Range
$56.31
$84.28
Volume
149,125 shs
Average Volume
168,754 shs
Market Capitalization
$2.67 billion
P/E Ratio
18.52
Dividend Yield
N/A
Price Target
$82.50

Ingevity MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
19.7% Upside
$82.50 Price Target
Short Interest
Bearish
2.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of Ingevity in the last 14 days
Based on 36 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.70%
From $6.05 to $7.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Basic Materials Sector

116th out of 224 stocks

Chemicals & Allied Products Industry

12th out of 17 stocks

NGVT stock logo

About Ingevity (NYSE:NGVT) Stock

Ingevity Corporation manufactures and sells specialty chemicals and activated carbon materials in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, motorcycles, trucks, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment comprises of pavement technologies, industrial specialties, and engineered polymers. It manufactures products derived from crude tall oil and lignin extracted from the kraft pulping process, as well as caprolactone monomers and derivatives derived from cyclohexanone and hydrogen peroxide. This segment's products are used in various applications comprising warm mix paving, pavement preservation, pavement reconstruction and recycling, oil well service additives, oil production, and downstream applications; and adhesives, agrochemical dispersants, lubricants, printing inks, industrial intermediates and oilfield, coatings, resins, elastomers, bioplastics, and medical devices. Ingevity Corporation was founded in 1964 and is headquartered in North Charleston, South Carolina.

Ingevity Price Performance

Shares of NGVT Stock traded up $0.19 during trading hours on Monday, hitting $68.91. The company had a trading volume of 149,125 shares, compared to its average volume of 218,313. Ingevity has a 12 month low of $56.31 and a 12 month high of $84.28. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of 18.52 and a beta of 1.85. The firm's fifty day moving average is $65.76 and its 200 day moving average is $65.00. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.50 and a current ratio of 2.54.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on NGVT shares. StockNews.com upgraded Ingevity from a "buy" rating to a "strong-buy" rating in a research note on Friday. TheStreet upgraded Ingevity from a "c" rating to a "b-" rating in a research note on Friday, May 27th.

Receive NGVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

NGVT Stock News Headlines

Ingevity (NYSE:NGVT) Upgraded by StockNews.com to Strong-Buy
Ingevity (NGVT) Shares Cross Above 200 DMA
Recap: Ingevity Q2 Earnings - Benzinga
Ingevity reports second quarter 2022 financial results
Earnings Preview: Ingevity - Benzinga
Ingevity (NGVT) Set to Announce Quarterly Earnings on Tuesday
See More Headlines
Receive NGVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

NGVT Company Calendar

Last Earnings
10/27/2021
Today
8/08/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Chemicals & allied products
Sub-Industry
N/A
Previous Symbol
NASDAQ:NGVT
Employees
1,850
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$82.50
High Stock Price Forecast
$84.00
Low Stock Price Forecast
$81.00
Forecasted Upside/Downside
+19.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$118.10 million
Pretax Margin
11.97%

Debt

Sales & Book Value

Annual Sales
$1.39 billion
Cash Flow
$8.16 per share
Book Value
$17.15 per share

Miscellaneous

Free Float
38,476,000
Market Cap
$2.67 billion
Optionable
Optionable
Beta
1.85

Key Executives

  • Mr. John C. Fortson (Age 55)
    Pres, CEO & Director
    Comp: $2.35M
  • Ms. Mary Dean Hall (Age 64)
    Exec. VP, CFO & Treasurer
    Comp: $1.03M
  • Ms. Stacy Lancaster Cozad (Age 51)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.39M
  • Mr. Stuart Edward Woodcock Jr. (Age 56)
    Exec. VP & Pres of Performance Materials
    Comp: $831.57k
  • Mr. Phillip John Platt (Age 41)
    Chief Accounting Officer, Corp. Controller & VP of Financial Planning
  • Mr. Daniel Gallagher
    VP of Investor Relations
  • John Nypaver
    VP of Treasurer & Investor Relations
  • Ms. Christine Stunyo
    Sr. VP & Chief HR Officer
  • Mr. Richard White (Age 59)
    Sr. VP of Performance Chemicals and Pres of Industrial Specialties & Pavement Technologies
  • Mr. Erik Ripple
    Sr. VP and Chief Growth & Innovation Officer













NGVT Stock - Frequently Asked Questions

Should I buy or sell Ingevity stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NGVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NGVT, but not buy additional shares or sell existing shares.
View NGVT analyst ratings
or view top-rated stocks.

What is Ingevity's stock price forecast for 2022?

2 equities research analysts have issued twelve-month price objectives for Ingevity's stock. Their NGVT share price forecasts range from $81.00 to $84.00. On average, they predict the company's share price to reach $82.50 in the next year. This suggests a possible upside of 19.7% from the stock's current price.
View analysts price targets for NGVT
or view top-rated stocks among Wall Street analysts.

How has Ingevity's stock performed in 2022?

Ingevity's stock was trading at $71.70 on January 1st, 2022. Since then, NGVT shares have decreased by 3.9% and is now trading at $68.91.
View the best growth stocks for 2022 here
.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our NGVT earnings forecast
.

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) issued its quarterly earnings results on Wednesday, October, 27th. The company reported $1.62 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.08. The firm earned $376.80 million during the quarter, compared to analysts' expectations of $354.29 million. Ingevity had a trailing twelve-month return on equity of 33.97% and a net margin of 9.61%. Ingevity's revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.79 earnings per share.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.52 billion-$1.65 billion, compared to the consensus revenue estimate of $1.59 billion.

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity Chief Executive Officer John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among the company's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by many different retail and institutional investors. Top institutional investors include Brown Advisory Inc. (1.85%), Rice Hall James & Associates LLC (1.20%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.55%), Leeward Investments LLC MA (0.41%), Patten & Patten Inc. TN (0.34%) and Loomis Sayles & Co. L P (0.31%). Insiders that own company stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends
.

How do I buy shares of Ingevity?

Shares of NGVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $68.91.

How much money does Ingevity make?

Ingevity (NYSE:NGVT) has a market capitalization of $2.67 billion and generates $1.39 billion in revenue each year. The company earns $118.10 million in net income (profit) each year or $3.72 on an earnings per share basis.

How many employees does Ingevity have?

Ingevity employs 1,850 workers across the globe.

How can I contact Ingevity?

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The official website for the company is www.ingevity.com. The company can be reached via phone at (844) 643-8489, via email at daniel.gallagher@ingevity.com, or via fax at 843-740-8165.

This page (NYSE:NGVT) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.